BRD2 and hepatitis B virus infection: The introduction of NAT either in minipools of plasma samples (MP-NAT) or in individual donation (ID-NAT) significantly reduced further the HBV transfusion–transmission residual risk by improving the detection of HBV primo-infection during the serological window period (WP) and by detecting HBsAg-negative occult hepatitis B virus infection (OBI) [11,12].